X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2023
Details:
Vanflyta (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2023
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
VANFLYTA® (quizartinib) is an oral, highly potent, type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Vanflyta (quizartinib) is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations and has been specifically developed for patients with FLT3-ITD positive AML.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
Submission based on QuANTUM-First results showing Vanflyta (quizartinib) an oral, highly potent and selective type II FLT3 inhibitor plus chemotherapy significantly improved overall survival compared to chemotherapy alone.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
Quizartinib has received Fast Track Designation from the U.S. FDA for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive, in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy.
Lead Product(s): Quizartinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Submission based on QuANTUM-First results showing Vanflyta (quizartinib) plus chemotherapy significantly improved overall survival compared to chemotherapy alone.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Positive results from Vanflyta (quizartinib) combined with standard induction and chemotherapy demonstrated statistically significant and meaningful improvement in OS in adult patients with newly diagnosed FLT3-ITD positive AML compared to standard chemotherapy alone.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2022
Details:
Vanflyta (quizartinib), an oral, highly potent and selective type II FLT3 inhibitor, is in phase 1/2 clinical development in pediatric and young adult patients with relapsed/refractory FLT3-ITD AML in Europe and North America.
Lead Product(s): Quizartinib,Cytarabine,Daunorubicin
Therapeutic Area: Oncology Product Name: Vanflyta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
